We Offer Worldwide Shipping
Login Wishlist

Varenicline tartrate

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1012

  • Specification : 98%(HPLC)

  • CAS number : 375815-87-5

  • Formula : C17H19N3O6

  • Molecular Weight : 361.35

  • PUBCHEM ID : 170362

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1012

Analysis Method

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

361.35

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

C1C2CNCC1C3=CC4=NC=CN=C4C=C23.C(C(C(=O)O)O)(C(=O)O)O

Synonyms

IUPAC Name

Density

Solubility

Flash Point

48.2 °F

Boiling Point

400.6ºC at 760 mmHg

Melting Point

206-208ºC

InChl

InChl Key

TWYFGYXQSYOKLK-WUUYCOTASA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:375815-87-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27235620

Abstract

This article reviews the current pharmacotherapy options available for the treatment of patients with substance use disorders. In the United States there are medications available to treat tobacco use disorders (nicotine replacement, bupropion, and varenicline), alcohol use disorders (naltrexone and acamprosate), and opioid use disorders (methadone and buprenorphine). These medications are likely underused and physicians should more readily prescribe for eligible patients.

KEYWORDS

Buprenorphine; Methadone; Naltrexone; Substance use disorder; Varenicline.

Title

Pharmacotherapy for Substance Use Disorders

Author

Jared Wilson Klein 1

Publish date

2016 Jul;

PMID

28925657

Title

Varenicline for Smoking Cessation

Author

Paul Crawford, Daniel Cieslak

Publish date

2017 Sep 19;

PMID

26391240

Abstract

The high prevalence of cigarette smoking and tobacco related morbidity and mortality in people with chronic mental illness is well documented. This review summarizes results from studies of smoking cessation treatments in people with schizophrenia, depression, anxiety disorders, and post-traumatic stress disorder. It also summarizes experimental studies aimed at identifying biopsychosocial mechanisms that underlie the high smoking rates seen in people with these disorders. Research indicates that smokers with chronic mental illness can quit with standard cessation approaches with minimal effects on psychiatric symptoms. Although some studies have noted high relapse rates, longer maintenance on pharmacotherapy reduces rates of relapse without untoward effects on psychiatric symptoms. Similar biopsychosocial mechanisms are thought to be involved in the initiation and persistence of smoking in patients with different disorders. An appreciation of these common factors may aid the development of novel tobacco treatments for people with chronic mental illness. Novel nicotine and tobacco products such as electronic cigarettes and very low nicotine content cigarettes may also be used to improve smoking cessation rates in people with chronic mental illness.

© BMJ Publishing Group Ltd 2015.

Title

Smoking Cessation and Reduction in People With Chronic Mental Illness

Author

Jennifer W Tidey 1, Mollie E Miller 2

Publish date

2015 Sep 21


Description :

Empty ...